Table of Contents
Hepatitis Research and Treatment
Volume 2010 (2010), Article ID 702748, 6 pages
http://dx.doi.org/10.1155/2010/702748
Clinical Study

Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C

1Department of Gastroenterology, Tokai University School of Medicine, Isehara 259-1193, Japan
2Department of Gastroenterology, Tokai University Hachioji Hospital, Tokyo 192-0032, Japan
3Department of Gastroenterology, Tokai University Tokyo Hospital, Tokyo 151-0053, Japan
4Department of Gastroenterology, Tokai University Oiso Hospital, Oiso 259-0198, Japan
5Ikegami General Hospital, Tokyo 146-8531, Japan
6Isehara Kyodo Hospital, Isehara 259-1132, Japan
7Japan Medical Alliance Ebina General Hospital, Ebina 243-0433, Japan
8Tomei-Atsugi Hospital, Atsugi 243-8571, Japan
9Hiratsuka City Hospital, Hiratsuka 254-0065, Japan
10Department of Community Health, Tokai University School of Medicine, Isehara 259-1193, Japan

Received 3 May 2010; Revised 26 June 2010; Accepted 29 June 2010

Academic Editor: Emmet B. Keeffe

Copyright © 2010 Makoto Numata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–I67, 2004. View at Google Scholar · View at Scopus
  4. J. G. McHutchison, M. Manns, K. Patel et al., “Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C,” Gastroenterology, vol. 123, no. 4, pp. 1061–1069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Shiffman, M. G. Ghany, T. R. Morgan et al., “Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C,” Gastroenterology, vol. 132, no. 1, pp. 103–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. R. Reddy, M. L. Shiffman, T. R. Morgan et al., “Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatmentnt,” Clinical Gastroenterology and Hepatology, vol. 5, no. 1, pp. 124–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. S. Conjeevaram, M. W. Fried, L. J. Jeffers et al., “Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1,” Gastroenterology, vol. 131, no. 2, pp. 470–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade et al., “Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,” Gastroenterology, vol. 128, no. 3, pp. 636–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Muir, J. D. Bornstein, and P. G. Killenberg, “Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2265–2271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy,” Nature Genetics, vol. 41, no. 10, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Sezaki, F. Suzuki, Y. Kawamura et al., “Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads,” Digestive Diseases and Sciences, vol. 54, no. 6, pp. 1317–1324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Watanabe, N. Enomoto, K. Koike et al., “Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan,” Hepatology Research, vol. 40, no. 2, pp. 135–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Tanaka, K. Tsukiyama-Kohara, K. Yamaguchi et al., “Significance of specific antibody assay for genotyping of hepatitis C virus,” Hepatology, vol. 19, no. 6, pp. 1347–1353, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Poynard, P. Marcellin, S. S. Lee et al., “Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus,” The Lancet, vol. 352, no. 9138, pp. 1426–1432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. J. G. Mchutchison, S. C. Gordon, E. R. Schiff et al., “Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” The New England Journal of Medicine, vol. 339, no. 21, pp. 1485–1492, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. G. L. Davis, R. Esteban-Mur, V. Rustgi et al., “Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group,” The New England Journal of Medicine, vol. 339, pp. 1493–1499, 1998. View at Google Scholar
  19. N. Hiramatsu, T. Oze, T. Yakushijin et al., “Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin,” Journal of Viral Hepatitis, vol. 16, no. 8, pp. 586–594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Lindahl, L. Stahle, A. Bruchfeld, and R. Schvarcz, “High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C,” Hepatology, vol. 41, no. 2, pp. 275–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. N. H. Afdhal, D. T. Dieterich, P. J. Pockros et al., “Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study,” Gastroenterology, vol. 126, no. 5, pp. 1302–1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. L. Shiffman, J. Salvatore, S. Hubbard et al., “Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha,” Hepatology, vol. 46, no. 2, pp. 371–379, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Iwasaki, H. Ikeda, Y. Araki et al., “Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C,” Hepatology, vol. 43, no. 1, pp. 54–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Kagawa, H. Shiozawa, S.-I. Kojima et al., “Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C,” Hepatology Research, vol. 38, no. 3, pp. 259–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Tanaka, K. Kiyosawa, T. Matsushima et al., “Egidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: a multi-institution analysis,” Journal of Gastroenterology and Hepatology, vol. 10, no. 5, pp. 538–545, 1995. View at Google Scholar · View at Scopus